Identification of Novel Inflammation-related Biomarkers for Early Detection of Anthracycline-induced Cardiotoxicity in Breast Cancer Patients

University Hospital Essen

Status: Unknown

Conditions: Cardiotoxicity; Breast Cancer; Heart Failure

Study type: Observational

Funder types: Other

Identifiers

NCT05298072

22-10590-BO

Details and patient eligibility

About

This study aims to identify possible set of inflammatory biomarkers before, during and after anthracycline-based chemotherapy in breast cancer patients to identify (sub)clinical chemotherapy-related cardiac dysfunctionCRCD to identify patients who would benefit from additional cardioprotective therapy.

Enrollment: 180 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• initial diagnosis of breast cancer
• planned Anthracycline-based therapy
• first-line chemotherapy
• first visit before initiation of chemotherapy

Exclusion criteria

• previous chemotherapy
• medical history of cardiac disease
• inflammation-modulating medication
• medication with RAS inhibitors
• pregnancy
• autoimmune disease
• drug addictions
• unwilling or unable to provide informed consent